by Fred Dumais | Mar 22, 2024 | News Release
MONTREAL, QUEBEC, March 22, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company’s Board of Directors. “We are very pleased...
by Fred Dumais | Mar 14, 2024 | News Release
Q1-24 revenues of $13.5 million, up 3% over Q1-23 Q1-24 adjusted EBITDA loss of $2.1 million compared to $2.2 million for Q1-23, down 6% Total Enerzair and Atectura prescriptions for the 12 months ending January 31, 2024, exceeded 78,000, up 130% over the 12...
by Fred Dumais | Mar 7, 2024 | News Release
MONTREAL, QUEBEC , March 7, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2024...
by Fred Dumais | Feb 13, 2024 | News Release
MONTREAL, QUEBEC, February 13, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company’s Board of Directors...
by Fred Dumais | Feb 2, 2024 | News Release
Original commercialization and supply agreement amended following global divestment of XIIDRA® SIMBRINZA® remains under Valeo Pharma exclusive promotion and distribution Proceeds from reimbursement to be used for debt reduction purposes Sagard credit facility amended...
by Fred Dumais | Jan 29, 2024 | News Release
Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4% over Q4-22 Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up...
